Sun.Dec 15, 2024

article thumbnail

Arnold & Porter Discusses CFPB Report on Privacy-Protection Gaps for Financial Service Customers

Reynolds Holding

The Consumer Financial Protection Bureau (the CFPB) recently released a report identifying limits in federal privacy protections afforded by the Fair Credit Reporting Act (FCRA) and Gramm-Leach-Bliley Act (the GLBA). The report strongly encourages state policymakers to consider how consumers are impacted by the FCRA and GLBA exemptions contained in all of the 19 [1] broad state consumer privacy laws enacted over the past six years.

Banking 49
article thumbnail

Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology

Benzinga

Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global stem cell banking market share will reach a value of USD 18.65 Billion by 2031 , with a CAGR of 18.30% during the forecast period (2024-2031). As cryopreservation and cell bank preparation techniques are getting advanced, the stem cell banking market is expanding rapidly.

Banking 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Valuation of Service Business

Equilest

Want to understand the intricacies of service business valuation? Dive into our detailed breakdown to learn how to assess and maximize your companys value! Valuation of Service Business If you own or manage a service-based business, knowing the value of your company is super important! Whether you're thinking about selling, looking for financing, or just want to understand the health of your business, a thorough valuation can offer amazing insights.

article thumbnail

Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology

Benzinga

Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global healthcare analytical testing services market size will reach a value of USD 15.55 Billion by 2031 , with a CAGR of 11.2% during the forecast period (2024-2031). The market's main driving factors are the number of companies in the pharmaceutical and medical device industries that outsource analytical testing services, increased clinical trials in need of analytical testing, and the rising emphasis on biosimil

article thumbnail

How to Leverage Intent Data for Better Outcomes

Speaker: Susan Spencer, Principal of Spencer Communications

Intent signal data can go a long way toward shortening sales cycles and closing more deals. The challenge is deciding which is the best type of intent data to help your company meet its sales and marketing goals. In this webinar, Susan Spencer, fractional CMO and principal of Spencer Communications, will unpack the differences between contact-level and company-level intent signals.

article thumbnail

Stuck in the Middle with ESG: What Companies Can Expect in 2025 & Beyond

Harvard Corporate Governance

Posted by Martha Carter, Matt Filosa, andFaten Alqaseer, Teneo, on Sunday, December 15, 2024 Editor's Note: Martha Carter is Vice Chair and Head of Governance Advisory, and Matt Filosa and Faten Alqaseer are Senior Managing Directors, at Teneo. This post is based on a Teneo memorandum by Ms. Carter, Mr. Filosa, Ms. Alqaseer, Kensey Biggs , Diana Lee , and Rose James.

113
113
article thumbnail

Pharming announces public cash offer to the shareholders of Abliva AB

Benzinga

Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (